Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.05 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including oligodendrocyte progenitor cells; strongest in lactotrophs | 0.75 |
| chemistry Open Targets | compounds already reach it: lorlatinib, plb1003, alectinib hydrochloride +9 | 1.00 |
| trials ClinicalTrials.gov | 3 Parkinson's trials, 0 stopped | 1.00 |
| literature PubMed | 12 Parkinson's papers of 16,125 | 0.66 |
| pathways Reactome | 11 pathways; mostly growth signalling | 0.60 |
No case: the score is under the bar. Receipt 5461
Sealed predictions
- ALK in oligodendrocytes, braak+0.04 (p 0.925) → -0.31 (p 0.414)receipt 5468
- ALK in dopamine neurons, braak+0.51 (p 0.163) → -0.34 (p 0.375)receipt 5469
Swarm cases
receipt 5469: ALK in dopamine neurons, braak
- power
- full sample +0.09 (p 0.715, n 18), 95% CI -0.39 to +0.54. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.12 (p 0.640, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.18 (p 0.476, n 18). could be the mix.
- skeptic
- leave-one-out range -0.02 to +0.23, sign flips 3; without severely affected donors +0.09 (p 0.715, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for ALK in dopamine neurons.
case closed: nothing better to follow up.
receipt 5468: ALK in oligodendrocytes, braak
- power
- full sample -0.09 (p 0.728, n 18), 95% CI -0.53 to +0.40. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.06 (p 0.820, n 18). does not hold up.
- composition
- oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: -0.32 (p 0.201, n 18). could be the mix.
- skeptic
- leave-one-out range -0.19 to +0.03, sign flips 3; without severely affected donors -0.09 (p 0.728, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for ALK in oligodendrocytes.
case closed: nothing better to follow up.
Receipts
loading the receipts